| 000 | 01822 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250514004605.0 | ||
| 264 | 0 | _c20011018 | |
| 008 | 200110s 0 0 eng d | ||
| 022 | _a0885-3185 | ||
| 024 | 7 |
_a10.1002/mds.1143 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRascol, O | |
| 245 | 0 | 0 |
_aIdazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. _h[electronic resource] |
| 260 |
_bMovement disorders : official journal of the Movement Disorder Society _cJul 2001 |
||
| 300 |
_a708-13 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAdrenergic alpha-Antagonists _xadverse effects |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xadverse effects |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aDyskinesia, Drug-Induced _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIdazoxan _xadverse effects |
| 650 | 0 | 4 |
_aLevodopa _xadverse effects |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aNeurologic Examination _xdrug effects |
| 650 | 0 | 4 |
_aParkinson Disease _xdrug therapy |
| 650 | 0 | 4 | _aPilot Projects |
| 700 | 1 | _aArnulf, I | |
| 700 | 1 | _aPeyro-Saint Paul, H | |
| 700 | 1 | _aBrefel-Courbon, C | |
| 700 | 1 | _aVidailhet, M | |
| 700 | 1 | _aThalamas, C | |
| 700 | 1 | _aBonnet, A M | |
| 700 | 1 | _aDescombes, S | |
| 700 | 1 | _aBejjani, B | |
| 700 | 1 | _aFabre, N | |
| 700 | 1 | _aMontastruc, J L | |
| 700 | 1 | _aAgid, Y | |
| 773 | 0 |
_tMovement disorders : official journal of the Movement Disorder Society _gvol. 16 _gno. 4 _gp. 708-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/mds.1143 _zAvailable from publisher's website |
| 999 |
_c11408746 _d11408746 |
||